CMPS
NASDAQCOMPASS Pathways Plc
Price$12.34+0.17 (+1.36%)
01:30 PM07:45 PM
News · 26 weeks65-31%
2026-01-182026-07-12
Mix3590d
- Other13(37%)
- Insider9(26%)
- Analyst4(11%)
- SEC Filings4(11%)
- Offering3(9%)
- Leadership2(6%)
Latest news
25 items- PRBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimeIssued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in
- PRCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from PsychotherapyPost-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapy Findings published in the Journal of Psychopharmacology Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented spe
- ANALYSTCOMPASS Pathways upgraded by Evercore ISI with a new price targetEvercore ISI upgraded COMPASS Pathways from In-line to Outperform and set a new price target of $21.00
- SECCOMPASS Pathways Plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - COMPASS Pathways plc (0001816590) (Filer)
- PRCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable ProfileNew 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further validating COMP360’s differentiated profile in highly chronic TRD Across two highly statistically significant positive Phase 3 trials, COMP360 is the first classic psychedelic¹ to consistently demonstrate rapid onset, significant durability and reproducibility of effect in TRD, one of psychiatry’s most difficult conditions in which to demonstrate efficacy COMP360 continues to demonstrate a generally well-tolerated and safe profile with no new safety findings Rolling NDA submission and ini
- PRCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Sel
- PRMulti-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient o
- PRKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic per
- PRA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearIssued on behalf of Helus Pharma™Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder has surpassed 86% enrollment, keeping the FDA Breakthrough-designated program on track for a topline data readout in Q4 2026.NEW YORK and TORONTO, June 26, 2026 /CNW/ -- USA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data readout on schedule. Late-stage psychiatric trials are notoriously hard to fill, which is why a clean enrollment update is meaningful. On June 24, 2026, Helus Pharm
- PRCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company's American Depositary Shares on the Nasdaq Globa
- INSIDERSEC Form 4 filed by Director Karydas Daphne4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Santini Gino4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Gover Justin D.4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Jonas Jeffrey M4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Riley Wayne Joseph4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcquade Robert4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Norton David Y4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 4 filed by Director Tregoning Kathleen4 - COMPASS Pathways plc (0001816590) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tregoning Kathleen3 - COMPASS Pathways plc (0001816590) (Issuer)
- SECSEC Form 8-K filed by COMPASS Pathways Plc8-K - COMPASS Pathways plc (0001816590) (Filer)
- PRCompass Pathways Elects Kathleen Tregoning to Board of DirectorsCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a
- PRCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are moti
- ANALYSTWolfe Research initiated coverage on COMPASS PathwaysWolfe Research initiated coverage of COMPASS Pathways with a rating of Outperform
- SECAmendment: SEC Form SCHEDULE 13G/A filed by COMPASS Pathways PlcSCHEDULE 13G/A - COMPASS Pathways plc (0001816590) (Subject)
- PRCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in men
CMPS FAQ
7 questionsWhat does COMPASS Pathways Plc do?
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.Where does CMPS stock trade?
COMPASS Pathways Plc (CMPS) is listed on NASDAQ.What sector and industry is CMPS in?
COMPASS Pathways Plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did COMPASS Pathways Plc go public?
COMPASS Pathways Plc (CMPS) completed its IPO in 2020.What are analysts saying about CMPS?
COMPASS Pathways Plc has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform with a $2100.00 price target on 2026-07-08. Recent price targets range from $600.00 to $2300.00.What companies are similar to CMPS?
Notable peers in the same industry include ATAI (AtaiBeckley Inc.), CODI (D/B/A Compass Diversified Holdings Shares of Beneficial Intere), CMPX (Compass Therapeutics Inc.). Compare CMPS side-by-side with any of them on Quantisnow.How can I track CMPS on Quantisnow?
Quantisnow aggregates COMPASS Pathways Plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMPS to receive live email and push alerts on every new disclosure.